doxorubicin + docetaxel sequential

Doxorubicin + docetaxel sequential refers to a chemotherapy regimen in which the anthracycline antibiotic doxorubicin is administered first, followed by the taxane docetaxel, rather than giving both drugs simultaneously. This approach has been studied primarily in breast cancer (both early-stage and metastatic), with dosing schedules such as three cycles of doxorubicin every two weeks followed by three cycles of docetaxel every two weeks[1][2][5]. Both agents are cytotoxic small molecules that disrupt cell division through different mechanisms—doxorubicin intercalates DNA and inhibits topoisomerase II, while docetaxel stabilizes microtubules and prevents their depolymerization. Sequential administration aims to maximize efficacy while managing toxicity profiles; studies have shown similar response rates compared to combination therapy but with some differences in side effects (e.g., more hand-foot syndrome or skin reactions with the sequential schedule)[1][2][5]. The regimen is used as primary or adjuvant chemotherapy for breast cancer.

Other names

doxorubicin and docetaxel sequentialsequential doxorubicin/docetaxel